Bausch + Lomb Corporation

BLCONYSE • USD
21.09 USD
↘ 0.05 (0.24%)AT CLOSE (03:59 PM EST)
20.87
↘ 0.22 (1.04%)
POST MARKET (AS OF 07:45 PM EST)
Post Market
AS OF 07:45 PM EST
20.87
↘ 0.22 (1.04%)
🔴Market: CLOSED

Bausch + Lomb Corporation (BLCO) trades at $21.09 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation side, BLCO appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$21.25
High?$21.29
Low?$20.95
Prev. Close?$21.14
Volume?525.9K
Avg. Volume?938.6K
VWAP?$21.12
Rel. Volume?0.56x
Bid / Ask
Bid?$20.69 × 200
Ask?$21.05 × 500
Spread?$0.36
Midpoint?$20.87
Valuation & Ratios
Market Cap?7.5B
Shares Out?357.4M
Float?46.4M
Float %?13.0%
P/E Ratio?N/A
P/B Ratio?1.17
EPS?-$0.31
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.
Employees
13.0K
Market Cap
7.6B
Industry
OPHTHALMIC GOODS
Listed
2022-05-06
Address
520 APPLEWOOD CRESCENT
VAUGHAN, A6 L4K 4B4
Phone: 908-541-5456
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
12
Momentum?
65
Short Sent.?
75
Piotroski F-Score?5/9Mixed
Altman Z-Score?1.10Distress
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.58%Elevated
Short Interest?2.6M
Days to Cover?2.3
Free Float46.4M
Avg Daily Volume1.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.56Adequate
Quick Ratio?1.04Adequate
Cash Ratio?0.26Low
Debt/Equity?0.79Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
87/100
P/E?
N/A▾
P/B?
Peers
100
S&P
94
1.17CHEAP▾
P/S?
Peers
100
S&P
80
1.39CHEAP▾
P/FCF?
Peers
100
S&P
29
29.9FAIR▾
EV/EBITDA?
Peers
100
S&P
61
13.1FAIR▾
EV/Sales?
Peers
100
S&P
71
2.24CHEAP▾
Returns & Efficiency
ROE?
S&P
14
-1.7%WEAK▾
ROA?
S&P
5
-0.8%WEAK▾
Cash Flow & Enterprise
FCF?$252.0M
Enterprise Value?$12.1B
Fundamentals ratios updated end of day